Showing 2,421 - 2,440 results of 18,130 for search 'significantly ((((less decrease) OR (((we decrease) OR (nn decrease))))) OR (a decrease))', query time: 0.83s Refine Results
  1. 2421
  2. 2422
  3. 2423

    Image 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
  4. 2424

    Image 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
  5. 2425

    Image 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
  6. 2426

    Table 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.docx by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
  7. 2427

    Table 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
  8. 2428

    Table 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
  9. 2429

    Image 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
  10. 2430

    Table 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
  11. 2431
  12. 2432
  13. 2433
  14. 2434
  15. 2435
  16. 2436
  17. 2437
  18. 2438

    Image1_The immunological and prognostic significance of the diabetes mellitus-related gene WFS1 in endometrial cancer.tif by Wenzhe Li (815057)

    Published 2024
    “…</p>Methods<p>Using the CTD, GeneCards, and GSEA databases, we identified WFS1 as a diabetes-related gene and then conducted an extensive investigation focusing on WFS1 in the context of EC. …”
  19. 2439

    Table2_The immunological and prognostic significance of the diabetes mellitus-related gene WFS1 in endometrial cancer.xlsx by Wenzhe Li (815057)

    Published 2024
    “…</p>Methods<p>Using the CTD, GeneCards, and GSEA databases, we identified WFS1 as a diabetes-related gene and then conducted an extensive investigation focusing on WFS1 in the context of EC. …”
  20. 2440

    Table3_The immunological and prognostic significance of the diabetes mellitus-related gene WFS1 in endometrial cancer.docx by Wenzhe Li (815057)

    Published 2024
    “…</p>Methods<p>Using the CTD, GeneCards, and GSEA databases, we identified WFS1 as a diabetes-related gene and then conducted an extensive investigation focusing on WFS1 in the context of EC. …”